AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00894504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1500 mg/m2 IV, Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
Study NCT02803593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-based information and coaching/support program
Description: The TICAA has three components in four languages (English, Mandarin Chinese, Korean, and Japanese): (a) social media sites; (b) interactive online educational sessions; and (c) online resources. The social media sites provide a mechanism by which participants can receive coaching/support from culturally matched peers and health care providers. The educational sessions provide information about general and sub-ethnic- specific topics related to breast cancer survivorship. The online resources include 35 Web links to resources related to breast cancer survivorship from scientific authorities and from general and sub-ethnic-specific health organizations/institutes.
Study NCT02803593 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: American Cancer Society information on breast cancer
Description: The American Cancer Society (ACS) webpage has a wide range of information on breast cancer including prevention, treatment, and ways to connect with breast cancer survivors.
Study NCT02803593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: American Cancer Society information on breast cancer
Description: The American Cancer Society (ACS) webpage has a wide range of information on breast cancer including prevention, treatment, and ways to connect with breast cancer survivors.
Study NCT02577588 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: re-activated T cells
Description: autologous reactivated T cells against p53
Study NCT00224029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin transdermal system
Description: 3.9 mg/day, 7.8 mg/day, 9.1 mg/day or 11.7 mg/day transdermal per titration
Study NCT00433017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: As a placebo for verteporfin photodynamic therapy (for masking purposes), patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.
Study NCT01793350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BC-DN-01 topically applied cream
Description: Phase 1 - week 1 - total daily dose 160mg benfotiamine as 8g BC-DN-01 Phase 1 - week 2 - total daily dose 320mg benfotiamine as 16g BC-DN-01 Phase 2 - for 12 weeks - total daily dose 320mg benfotiamine as 16g BC-DN-01
Study NCT01109628 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein drink
Description: Twice a day during 6 months
Study NCT01109628 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Twice a day during 6 months
Study NCT05274087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous autoinjector
Study NCT04112550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone Hydrochloride
Description: FDA approved medication to treat pain
Study NCT04112550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone-Acetaminophen
Description: FDA approved medication to treat pain
Study NCT02006433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Local anesthesis, MRI and CT scan of the brain followed by implantation of the stimulation device
Study NCT00885378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin plus metformin IR
Description: Tablets, Oral, 2.5 mg, Twice daily, 12 weeks
Study NCT00885378 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus metformin IR
Description: Tablets, Oral, Placebo, Twice daily, 12 weeks
Study NCT04379765 — intervention group
Intervention type: BEHAVIORAL
Intervention: Exercise and physical therapy
Description: Decompression operation
Study NCT01759394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag maleate 40 mg
Description: Avatrombopag maleate 40 mg (2 x 20 mg tablets- all doses are expressed as avatrombopag, the amount of free base) given with 240 mL water in three single oral doses, one during each of three treatment periods. Participants randomized to one of three treatment sequences:~* Fed, Fed, Fasted; or~* Fed, Fasted, Fed; or~* Fasted, Fed, Fed~During the Fasted period, participants must have fasted for at least a 10-hour overnight fast and to refrain from eating for 4 hours.~During the Fed period, participants were allowed approximately 30 minutes to eat a low-fat breakfast and required to take the drug within 15 minutes of completion of breakfast.~Randomization Phase consists of three single-dose treatment periods:~Treatment Period 1 and 2 separated by a 7-day washout interval. Treatment Period 2 and 3 separated by a 28-day washout interval. Treatment period 3 and the Follow-up/ Termination Visit will be separated by a 30-day (+1 day) washout interval.
Study NCT04193553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib will be administered continuously but patient's follow-up visits will be scheduled monthly.~The starting dose of study treatment is 24mg, once daily, at the same time. Recommendations for dose reductions will be respected according to BI Lenvatinib.~If a patient misses a dose, and it cannot be taken within 12 hours, then that dose should be skipped and the next dose should be taken at the usual time of administration.~Study treatments will be continued until a treatment discontinuation criteria is met.
Study NCT04193553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered continuously but patient's follow-up visits will be scheduled monthly.~The starting dose of study treatment is 24mg, once daily, at the same time. Recommendations for placebo dose reductions are the same as for Lenvatinib. If a patient misses a dose, and it cannot be taken within 12 hours, then that dose should be skipped and the next dose should be taken at the usual time of administration.~Study treatments will be continued until a treatment discontinuation criteria is met.~In case disease progression, patients in control arm could switch in the Lenvatinib + BSC arm.
Study NCT04193553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best supportive care
Description: At any time during the study, patients should receive best supportive care. Best Supportive care as medically indicated for the patient's well-being may be prescribed at the investigator's discretion. Based on the patient's condition, it may consist (but not limited) of analgesics, antibiotics, steroids, blood transfusion, antiemetics, antidepressants/anxiolytics, nutritional counselling, psychological support, palliative radiotherapy...
Study NCT04193553 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best supportive care
Description: At any time during the study, patients should receive best supportive care. Best Supportive care as medically indicated for the patient's well-being may be prescribed at the investigator's discretion. Based on the patient's condition, it may consist (but not limited) of analgesics, antibiotics, steroids, blood transfusion, antiemetics, antidepressants/anxiolytics, nutritional counselling, psychological support, palliative radiotherapy...
Study NCT00060372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Given IV
Study NCT00060372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: Given IV
Study NCT02812225 — intervention group
Intervention type: DEVICE
Intervention: BrainPulse
Description: Jan Medical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle, referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to the brain motion using an array of sensors placed on the head.
Study NCT01760213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBT delivered via Internet
Study NCT01658254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey by email
Description: The intervention consists in an email to be sent to the sponsor and/or principal investigator of randomly assigned trials. This email will notify them that their trial's primary completion date is over a year old and will ask the reasons why they have not posted results on the registry. Several reasons will be proposed, and investigators or sponsors will be asked to reply by sending back an email or through a website where the same questions will appear. A follow-up email will systematically be sent 7 days after, with similar content (appendix2). The emails will be sent as direct emails, without attached files, with the edit subject Posting basic results. The controlled group will receive no intervention.
Study NCT01709409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curosurf-Group1
Description: Maximum of 3 doses are administered to infants diagnosed with RDS.
Study NCT01709409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BLES-group 2
Description: Maximum of 3 doses are administered to infants with RDS
Study NCT03278847 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Received enteral (milk) feeds during therapeutic hypothermia
Description: In the enteral component of nutrition, the health technology to be assessed is the gradual introduction of enteral (milk) feeds during therapeutic hypothermia:~* Included in this is any type of milk (e.g. expressed maternal breast milk, expressed donor breast milk and artificial formula)~* This health technology includes different routes of administering enteral feeds such as nasogastric tube (gavage feeding) and bottle~* This health technology also includes different rates of increasing enteral feeds (for example by 15ml/kg/day, by 30ml/kg/day or faster)
Study NCT03278847 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Enteral (milk) feeds withheld during therapeutic hypothermia
Description: Withholding enteral feeds (keeping a baby nil per os) for the duration of hypothermia.
Study NCT03278847 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Received parenteral nutrition during therapeutic hypothermia
Description: In the parenteral component, the health technology being assessed is administration of parenteral nutrition during therapeutic hypothermia:~* Included in this are different compositions of parenteral nutrition (for example standard, pre-prepared bags of nutrition and individually tailored parenteral nutrition)~* This health technology includes different routes of administration of parenteral nutrition such as via a peripheral intravenous cannula, percutaneous central venous catheter ('long line') or umbilical venous catheter.~* This health technology also includes different volumes of parenteral nutrition (e.g. 40ml/kg/day, 60ml/kg/day or greater).
Study NCT03278847 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Did not receive parenteral nutrition during therapeutic hypothermia
Description: Received standard intravenous fluids (10% dextrose with additional electrolytes added where required) for the duration of hypothermia.
Study NCT03635086 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV-CHIK lyophilised formulation, low dose
Description: MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, lyophilized low dose (powder for suspension in water for intramuscular \[IM\] injection): 5x10\^4 ±0.5 log tissue culture infectious dose 50 (TCID50)/dose.
Study NCT03635086 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV-CHIK liquid frozen formulation, low dose
Description: MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, liquid frozen low dose (suspension for IM injection): 1x10\^5 ±0.5 log TCID50/dose.
Study NCT03635086 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV-CHIK SPS® formulation, low dose
Description: MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, liquid SPS® low dose (suspension for IM injection): 1x10\^5 ±0.5 log TCID50/dose.
Study NCT03635086 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV-CHIK liquid frozen formulation, high dose
Description: MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, liquid frozen high dose (suspension for IM injection): 1x10\^6 ±0.5 log TCID50/dose.
Study NCT03635086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile physiological saline solution (0.9% sodium chloride \[NaCl\]), administered by IM injection.
Study NCT03569592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overdose Prevention Intervention
Description: Evaluate an overdose prevention education with incarcerated people living with HIV/AIDS.
Study NCT03494465 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PHACOEMULSIFICATION
Description: Standard phacoemulsification with intraocular lens implant will be perform within 60 days after allocation. If IOP target is not achieve, patients will be treated as in medical treatment group
Study NCT03494465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDICAL GLAUCOMA TREATMENT
Description: The escalation of topical hypotensive medications will be carried out with the following sequence: 1. single topical medication; 2. double topical therapy; 3. triple topical therapy. Beginning, with the exception of individual contraindications, with prostaglandin analogs, followed by topical beta-blockers, carbonic anhydrase inhibitors and finally alpha-agonists.Target IOP will be used in both groups to inform the need of escalation of therapy; in patients with ocular hypertension the target IOP will be 21 mmHg. In patients with mild glaucoma target IOP will be 18 mmHg, and in patients with moderate glaucoma the target IOP will be 15 mmHg.
Study NCT02001909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: single oral dose (s.d.) 160 mg (four 40 mg tablets) of regorafenib on two occasions (Day 1, Period 1, and Day 1, Period 2) separated by a washout period of at least 14 days
Study NCT02001909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neomycin
Description: 1 g tid (three times a day) regimen of Neomycin (oral) on five days in Period 2 starting 4 days before regorafenib intake on day 1 in period 2.
Study NCT04088045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autologous platelet rich plasma and 5% dextrose solution injections.
Description: One group of patients will receive autologous platelet rich plasma injection into the knee joint and pes anserinus complex. The other group will receive both PRP injections into the knee joint and pes anserinus complex, and prolotherapy of 5% dextrose solution to the genicular nerves.~Dextrose solutions are injected to the genicular nerves.
Study NCT01518907 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
Description: Subdermal dose
Study NCT03316807 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 60 µg dose hepatitis B vaccine
Description: three-dose, 60 µg per dose
Study NCT03316807 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20 µg dose hepatitis B vaccine
Description: three-dose, 20 µg per dose
Study NCT04569019 — intervention group
Intervention type: OTHER
Intervention: Vacciantion status in health care workers
Description: Education among HCW about benefits of influenza vaccination. Using posters, email, conversations, informations about vaccination used during vaccination Vaccinating during working hours Vaccinating for free Vaccinating inside departments ( not in special clinic)
Study NCT00760344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-472
Description: SYR-472 3.125 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
Study NCT00760344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-472
Description: SYR-472 12.5 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
Study NCT00760344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-472
Description: SYR-472 50 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
Study NCT00760344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-472
Description: SYR-472 100 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
Study NCT00760344 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SYR-472 placebo-matching tablets, orally, once daily with lifestyle modification and/or metformin therapy for up to 12 weeks.
Study NCT00760344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin 100 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
Study NCT01708434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera® System
Description: Focused ultrasound energy delivered below the surface of the skin
Study NCT03329300 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Family-based Behavioral Treatment (FBT)
Description: Family-based behavioral treatment (FBT) involves working with children and caregivers to modify diet and physical activity using behavioral strategies such as problem solving, goal setting, and self-monitoring. Children and caregivers will meet in group format on a weekly basis for 6 months. There will be 24 group session total, covering a variety of topics including nutrition, physical activity, and other aspects of health and wellness.
Study NCT04218747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VA 365 Demonstration Benefits
Description: Reducing hunger 365 days a year in households with school children by transforming schools into food hubs ( free breakfast, lunch, supper, and food backpacks for the weekend) and providing nutrition education to parents.
Study NCT02926911 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery +/- radiation choice for endocrine therapy
Study NCT02926911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Monitoring
Description: Choice for endocrine therapy
Study NCT03482362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine Tartrate
Description: Intravenous administration of vinorelbine on day 1 and day 8 in a dose of 30 mg/m2. One treatment cycle is 21 days.
Study NCT02669615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan HCl for injection (propylene glycol free)
Description: During the study period, patients will receive 200 mg/m\^2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2.
Study NCT02430753 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Irreversible Electroportion For Lung Neoplasms accompanied by Respiratory Function Insufficiency guide with ultrasound or/and CT.
Study NCT02430753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife
Study NCT01181791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri
Description: Lactobacillus reuteri DSM will be given at a dose of 1x108 colony forming units (CFU)/day
Study NCT01181791 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo consists of an identical formulation except that the L. reuteri is not present.
Study NCT01895036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Study NCT03956693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEADS: UP
Description: HEADS: UP comprises 9 x 2.5 hour mindfulness teaching sessions and a silent retreat in week 7. Course materials include accessible information packs and resources to complement class-based sessions.~The first week of the 9-week course is an introductory class. The purpose of the introductory class is to give participants the opportunity to meet the trainers and to decide if they want to learn more about mindfulness. The introductory session also allows participants to meet other people on the course and to share their (stroke) stories.
Study NCT02168322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: collagen membrane
Description: bovine collagen membrane used for selective tissue regeneration
Study NCT02168322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: collagen membrane
Description: collagen bovine occlusive membrane for selective tissue regneration
Study NCT02165995 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motor Mapping
Description: Motor mapping performed using nTMS system before surgery, then again at 1, 3, 6, and 12 months following surgery. Pads to monitor movements placed on face, arms and legs. A coil that is used to deliver stimulation will be placed on head. During stimulation, participant be asked to move certain muscles and will be monitored for motor responses over the course of 20 to 30 minutes.
Study NCT02165995 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Speech Mapping
Description: Speech mapping performed using nTMS system before surgery, then again at 1, 3, 6, and 12 months following surgery. Participant shown 95 black-and-white drawings of common objects and asked to name them. During stimulation, participant asked to name the objects again and will be monitored for changes in speech or delays. This should take about 1½-2 hours to complete.
Study NCT03004404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03004404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: powder for reconstitution of an oral solution (PfoS)